ClinicalTrials.gg

Program

Aripiprazole

Also written as “aripiprazole”, “Aripiprazole IM Depot” and “Antidepressant + Aripiprazole”.

Its studies are mostly in Schizophrenia · Bipolar Disorder · Depressive Disorder, Major · Tourette Syndrome · Autistic Disorder, led by 10 companies.

Furthest: phase 4, since Mar 26, 2004124 company-led studies, 1 open or runningNext primary completion: Sep 5, 2027

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka1120 open or runningphase 4since Mar 26, 2004May 7, 2002none ahead
Johnson & Johnson40 open or runningphase 4since Feb 10, 2012Feb 10, 2012none ahead
Abdi İbrahim Otsuka10 open or runningphase 4since Feb 23, 2016Feb 23, 2016none ahead
Chengdu Kanghong Pharmaceutical Group10 open or runningno phasesince Jul 24, 2017Jul 24, 2017none ahead
cmg-pharmaceutical-co-ltd10 open or runningphase 1since Jun 4, 2015Jun 4, 2015none ahead
CSPC Pharmaceutical Group11 open or runningno phasesince Mar 23, 2026Mar 23, 2026Sep 5, 2027NCT07547384
genovate-biotechnology-co-ltd10 open or runningphase 4since Oct 8, 2007Oct 8, 2007none ahead
Genuine Research Center, Egypt10 open or runningphase 1since Mar 27, 2023Mar 27, 2023none ahead
GlaxoSmithKline10 open or runningphase 1since Aug 18, 2011Aug 18, 2011none ahead
H. Lundbeck10 open or runningphase 3since Oct 7, 2013Oct 7, 2013none ahead

Also a collaborator on its studies: pra-health-sciences, covance and Pfizer.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 44 studies since Apr 2, 2009.

  1. May 2, 20172 phase 1 studies in SchizophreniaOtsuka · NCT03150771, NCT03287505
  2. May 11, 2017Phase 3 study in SchizophreniaOtsuka · NCT03172871 · 436 enrolled · China
  3. Jul 24, 2017Chengdu Kanghong Pharmaceutical Group's first study: no phase study in BioequivalenceNew to Chengdu Kanghong Pharmaceutical GroupChengdu Kanghong Pharmaceutical Group · NCT03232710 · 66 enrolled · China
  4. Sep 11, 2017Phase 1 study in SchizophreniaOtsuka · NCT03285503 · 12 enrolled · China
  5. Dec 13, 2017Phase 4 study in SchizophreniaOtsuka · NCT03376763 · 201 enrolled · Korea, Republic of
  6. Mar 27, 20182 phase 3 studiesOtsuka · NCT03487783, NCT03487770
  7. May 25, 2018Phase 4 study in SchizophreniaOtsuka · NCT03568500 · 44 enrolled · United Kingdom
  8. Sep 5, 2018Phase 4 study in Tourette SyndromeOtsuka · NCT03661983 · 36 enrolled · United States, Canada, Hungary
  9. Feb 12, 2019Phase 1 study in SchizophreniaOtsuka · NCT03854409 · 72 enrolled · United States
  10. Mar 21, 2019Phase 3 study in SchizophreniaOtsuka · NCT03892889 · 277 enrolled · United States
  11. Jul 19, 2019Phase 2 study in SchizophreniaOtsuka · NCT04030143 · 266 enrolled · United States
  12. Mar 27, 2023Genuine Research Center, Egypt's first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT05804721 · 29 enrolled · Egypt
  13. Mar 29, 2024No phase study in Mental DisordersOtsuka · NCT06372210 · 54 enrolled · United States
  14. Mar 23, 2026CSPC Pharmaceutical Group's first study: no phase study in SchizophreniaNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT07547384 · 116 planned

Ahead

  1. Sep 5, 2027Primary completion: no phase study in SchizophreniaCSPC Pharmaceutical Group · NCT07547384

TargetBeta

“Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
brexpiprazoleruleOtsukaphase 470

Studies

The newest 60 of 124 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07547384Schizophrenia–Not yet recruitingCSPC Pharmaceutical GroupSep 5, 2027116
NCT06372210Mental Disorders · United States–CompletedOtsukaJul 19, 202354
NCT05804721Healthy · Egypt1CompletedGenuine Research Center, EgyptNov 7, 202229
NCT04030143Schizophrenia · United States2CompletedOtsukaJul 8, 2020266
NCT03892889Schizophrenia · United States3TerminatedOtsukaAug 12, 2020277
NCT03854409Schizophrenia · United States1CompletedOtsukaApr 5, 201972
NCT03661983Tourette Syndrome · United States, Canada, Hungary4TerminatedOtsukaJun 30, 202036
NCT03568500Schizophrenia · United Kingdom4CompletedOtsukaMay 21, 201944
NCT03487783Tourette Syndrome · China3CompletedOtsukaFeb 14, 2020121
NCT03487770Autistic Disorder · China3CompletedOtsukaApr 21, 2020111
NCT03376763Schizophrenia · Korea, Republic of4CompletedOtsukaNov 19, 2021201
NCT03285503Schizophrenia · China1CompletedOtsukaOct 14, 201912
NCT03232710Bioequivalence · China–UNKNOWNChengdu Kanghong Pharmaceutical GroupApr 30, 201866
NCT03287505Schizophrenia · China1CompletedOtsukaNov 8, 201924
NCT03172871Schizophrenia · China3CompletedOtsukaJul 22, 2019436
NCT03150771Schizophrenia · United States1CompletedOtsukaApr 18, 201836
NCT02722967Schizophrenia · United States2CompletedOtsukaSep 201649
NCT02697045Schizophrenia · Turkey4CompletedAbdi İbrahim OtsukaMar 31, 201823
NCT02634463Immunoassay · Belgium1CompletedJohnson & JohnsonNov 9, 201681
NCT02501109Schizophrenia1Completedcmg-pharmaceutical-co-ltdFeb 201636
NCT02462473Schizophrenia · United States2TerminatedJohnson & JohnsonJan 20169
NCT02435836Schizophrenia3TerminatedOtsukaDec 2012631
NCT02220712Schizophrenia · Japan1CompletedOtsukaApr 201517
NCT02091882Device Latency · United States4CompletedOtsukaApr 18, 201430
NCT02054702Schizophrenia3CompletedOtsukaJun 201497
NCT01981811Schizophrenia · United States2WithdrawnOtsukaMay 20140
NCT01959035Schizophrenia · United States3CompletedH. LundbeckMar 201588
NCT01942161Schizophrenia · Japan3CompletedOtsukaNov 2014106
NCT01942148Schizophrenia · Japan3CompletedOtsukaNov 201568
NCT01909466Schizophrenia · United States1CompletedOtsukaMar 2014141
NCT01870999Schizophrenia · United States1CompletedOtsukaOct 200841
NCT01727713Tourette Syndrome · United States, Canada, Hungary and more3CompletedOtsukaAug 2014110
NCT01727700Tourette Syndrome · United States, Canada, Germany and more3CompletedOtsukaAug 2013133
NCT01710709Bipolar I · United States, Canada, France and more3CompletedOtsukaNov 2016748
NCT01683058Schizophrenia · United States, Croatia, Latvia3CompletedOtsukaFeb 201474
NCT01663532Schizophrenia · United States, Croatia, Latvia3CompletedOtsukaAug 2013340
NCT01646827Schizophrenia · United States1CompletedOtsukaApr 201337
NCT01617460Autistic Disorder · Japan3CompletedOtsukaOct 201686
NCT01617447Autistic Disorder · Japan3CompletedOtsukaJun 201592
NCT01607762Healthy · Belgium1CompletedJohnson & JohnsonApr 201231
NCT01552772Schizophrenia · United States1CompletedOtsukaApr 201260
NCT01592201Schizophrenia · Korea, Republic of4TerminatedJohnson & JohnsonJun 201313
NCT01509053Schizophrenia · Belgium, Bulgaria, Canada3TerminatedOtsukaOct 201230
NCT01432444Schizophrenia · United States, Canada3CompletedOtsukaDec 2013493
NCT01438060Alzheimer Disease3CompletedOtsukaJul 2010232
NCT01429831Depressive Disorder, Major · Taiwan4CompletedOtsukaMay 2013300
NCT01424449Depressive Disorder · United Kingdom1CompletedGlaxoSmithKlineJul 20107
NCT01418352Tourette Syndrome · United States, Bulgaria, Germany and more3CompletedOtsukaMar 12, 201483
NCT01418339Tourette Syndrome · United States, Canada, Hungary and more3CompletedOtsukaNov 6, 2013135
NCT01416441Tourette Syndrome · United States, Bulgaria, Canada and more3CompletedOtsukaMar 13, 2014170
NCT01227668Irritability Associated With Autistic Disorder · United States4CompletedOtsukaJun 20, 2012215
NCT01149655Schizophrenia · United States, India, Malaysia and more3CompletedOtsukaNov 2013252
NCT01129882Schizophrenia · United States, Argentina, Australia and more3CompletedOtsukaDec 6, 2018709
NCT01123707Depressive Disorder, Major3TerminatedOtsukaSep 27, 2011173
NCT01122927Mania · United States, Bulgaria, Croatia and more3TerminatedOtsukaAug 2014524
NCT01111565Depressive Disorder, Major · United States, Canada, Croatia and more3TerminatedOtsukaSep 1, 2011137
NCT01111552Depressive Disorder, Major · United States, Australia, Bulgaria and more3TerminatedOtsukaSep 27, 2011237
NCT01111539Depressive Disorder, Major · United States, Estonia, Finland and more3TerminatedOtsukaSep 20, 2011211
NCT01001702Schizophrenia · Argentina, Croatia, India and more3CompletedOtsukaJul 201285
NCT00882362Depressive Disorder, Major · Japan3CompletedOtsukaJul 2012155

How it is read

Names in the registry

  • “Aripiprazole”, 81 entries
  • “aripiprazole”, 13 entries
  • “Aripiprazole IM Depot”, 7 entries
  • “Antidepressant + Aripiprazole”, 2 entries
  • “Aripiprazole for Injection”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.